Skip to main content
Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
9.20
+0.15 (1.66%)
May 19, 2025, 4:00 PM - Market closed

Adaptive Biotechnologies Revenue by Segment
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021
MRD
156.62M 145.53M 136.14M 123.34M 113.94M 102.74M 100.08M 95.37M
MRD Growth
37.46% 41.65% 36.03% 29.33% 25.53% 17.90% 32.40% 33.39%
Immune Medicine
32.90M 33.43M 41.14M 45.43M 60.56M 67.54M 79.61M 94.23M
Immune Medicine Growth
-45.67% -50.50% -48.32% -51.79% -35.27% -31.20% -13.89% 6.86%

Immune Medicine Revenue Breakdown
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021
Immune Medicine Service
20.54M 19.98M 23.27M 23.06M 22.42M 24.96M 28.66M 29.98M
Immune Medicine Service Growth
-8.37% -19.96% -18.79% -23.09% -29.43% -21.46% 2.98% 1.83%
Collaboration
12.36M 13.45M 17.87M 22.37M 38.15M 42.58M 50.95M 64.26M
Collaboration Growth
-67.59% -68.41% -64.93% -65.19% -38.27% -35.86% -21.15% 9.38%

Adjusted EBITDA by Segment
Period Ending Mar 31, 2025Dec 31, 2024
Immune
-24.52M -26.01M
MRD
-28.08M -41.22M

Operating Metrics

Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Number of Clonoseq Tests Delivered
82.18K 76.11K 70.84K 66.31K 61.46K 56.50K 51.34K 45.92K
Number of Clonoseq Tests Delivered Growth
33.72% 34.71% 37.98% 44.41% 48.98% 53.23% 54.67% 53.64%

MRD Revenue Breakdown
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021
Service
144.12M 133.03M 123.64M 115.84M 109.44M 102.74M 98.08M 93.37M
Service Growth
31.69% 29.48% 26.06% 24.07% 24.69% 26.61% 37.00% 41.48%
Regulatory Milestone
12.50M - 12.50M 7.50M 4.50M - - -
Regulatory Milestone Growth
177.78% - - - - - - -
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.